Replies to post #80699 on Biotech Values

[DewDiligence]

Survey of 200 rheumatologists shows BMY’s Orencia is outdueling Actemra, Simponi, and Cimzia in the RA second-line biologic setting (i.e. the third-line setting overall, following methotrexate in the first line and Humira, Enbrel, or Remicade in the second line):

http://finance.yahoo.com/news/Orencia-Early-Leader-Among-prnews-2333906830.html?x=0&.v=1

Comments?